Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2015

Study Completion Date

August 31, 2016

Conditions
Malignant GliomaGlioblastoma MultiformeAnaplastic AstrocytomaHigh Grade Glioma
Interventions
BIOLOGICAL

CAN-2409

Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.

DRUG

Valacyclovir

Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3

DRUG

Temozolomide

Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.

RADIATION

Radiation therapy

Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.

Trial Locations (4)

43210

The Ohio State University Medical Center, Dept. Neurological Surgery, Columbus

60637

The University of Chicago, Chicago

77030

The Methodist Hospital Neurological Institute, Houston

91010

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Candel Therapeutics, Inc.

INDUSTRY

NCT00589875 - Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | Biotech Hunter | Biotech Hunter